Merus N.V. (MRUS)
NASDAQ: MRUS
· Real-Time Price · USD
67.25
0.31 (0.46%)
At close: Aug 15, 2025, 3:59 PM
67.44
0.28%
After-hours: Aug 15, 2025, 05:55 PM EDT
0.46% (1D)
| Bid | 65.23 |
| Market Cap | 5.09B |
| Revenue (ttm) | 56.23M |
| Net Income (ttm) | -385.52M |
| EPS (ttm) | -5.58 |
| PE Ratio (ttm) | -12.05 |
| Forward PE | -13.32 |
| Analyst | Buy |
| Ask | 69 |
| Volume | 262,145 |
| Avg. Volume (20D) | 1,122,704 |
| Open | 66.56 |
| Previous Close | 66.94 |
| Day's Range | 66.35 - 67.44 |
| 52-Week Range | 33.19 - 67.59 |
| Beta | 1.09 |
About MRUS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MRUS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MRUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Merus has released their quartely earnings
on Aug 5, 2025:
Next Earnings Release
Merus N.V. is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-2.83%
Merus shares are trading lower after the company r...
Unlock content with
Pro Subscription
2 months ago
-7.75%
Merus shares are trading lower following its $300 million public offering announcement.
2 months ago · seekingalpha.com
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From MerusMRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative...
